Top

Published in:

01-07-2016 | Review Article

Combinational strategies of metformin and chemotherapy in cancers

Authors: Hui-Hui Zhang, Xiu-Li Guo

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2016

Abstract

Chemotherapeutic regimens are the most common treatment to inhibit tumor growth, but there is great variability in clinical responses of cancer patients; cancer cells often develop resistance to chemotherapeutics which results in tumor recurrence and further progression. Metformin, an extensively prescribed and well-tolerated first-line therapeutic drug for type 2 diabetes mellitus, has recently been identified as a potential and attractive anticancer adjuvant drug combined with chemotherapeutic drugs to improve treatment efficacy and lower doses. In this review, we summarized the molecular mechanisms underlying anticancer effects of metformin, which included insulin- and AMPK-dependent effects, selectively targeting cancer stem cells, reversing multidrug resistance, inhibition of the tumor metastasis and described the antineoplastic effects of metformin combined with chemotherapeutic agents in digestive system cancers (colorectal, gastric, hepatic and pancreatic cancer), reproductive system cancers (ovarian and endometrial cancer), prostate cancer, breast cancer, lung cancer, etc. Moreover, the clinical trials regarding metformin in combination of chemotherapeutic drugs were presented and the clinical obstacle or limitation related to the potential role of metformin in cancer treatment was also discussed in this review.

Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18(5):460–466. doi:10.1016/j.copbio.2007.10.007 CrossRefPubMed

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265–273. doi:10.1038/nrc2620 CrossRefPubMed

Drews RE, Shulman LN (2010) Update in hematology and oncology. Ann Intern Med 152(10):655–662. doi:10.7326/0003-4819-152-10-201005180-00244 CrossRefPubMed

Kim HJ, Kwon H, Lee JW, Kim HJ, Lee SB, Park HS, Sohn G, Lee Y, Koh BS, Yu JH, Son BH, Ahn SH (2015) Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast Cancer Res 17:64. doi:10.1186/s13058-015-0574-3 CrossRefPubMedPubMedCentral

Kong F, Gao F, Liu H, Chen L, Zheng R, Yu J, Li X, Liu G, Jia Y (2015) Metformin use improves the survival of diabetic combined small-cell lung cancer patients. Tumour Biol 36(10):8101–8106. doi:10.1007/s13277-015-3549-1 CrossRefPubMed

Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F, Xue Y (2013) Effects of metformin on CD133 + colorectal cancer cells in diabetic patients. Plos One 8(11):e81264. doi:10.1371/journal.pone.0081264 CrossRefPubMedPubMedCentral

Donadon V, Balbi M, Mas MD, Casarin P, Zanette G (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30(5):750–758. doi:10.1111/j.1478-3231.2010.02223.x CrossRefPubMed

Kowall B, Stang A, Rathmann W, Kostev K (2015) No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf 24(8):865–874. doi:10.1002/pds.3823 CrossRefPubMed

Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71(9):3196–3201. doi:10.1158/0008-5472.can-10-3471 CrossRefPubMedPubMedCentral

10.

Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, Bae-Jump VL (2012) Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol 125(2):458–469. doi:10.1016/j.ygyno.2012.01.009 CrossRefPubMedPubMedCentral

11.

Simon D, Balkau B (2010) Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes; 59:1254–1260. Diabetes 59(11):e25. doi:10.2337/db10-0937 CrossRefPubMed

12.

Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928. doi:10.1038/nrc2536 CrossRefPubMed

13.

Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, Kurshan N, Mejia W, Santopietro S, Yakar S, Wood TL, LeRoith D (2010) Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70(2):741–751. doi:10.1158/0008-5472.can-09-2141 CrossRefPubMedPubMedCentral

14.

Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9(5):1092–1099. doi:10.1158/1535-7163.mct-09-1186 CrossRefPubMed

15.

Hardie DG, Ross FA, Hawley SA (2012) AMP-activated protein kinase: a target for drugs both ancient and modern. Chem Biol 19(10):1222–1236. doi:10.1016/j.chembiol.2012.08.019 CrossRefPubMed

16.

Griss T, Vincent EE, Egnatchik R, Chen J, Ma EH, Faubert B, Viollet B, DeBerardinis RJ, Jones RG (2015) Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. Plos Biol 13(12):e1002309. doi:10.1371/journal.pbio.1002309 CrossRefPubMedPubMedCentral

17.

Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S (2013) Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32(12):1475–1487. doi:10.1038/onc.2012.181 CrossRefPubMed

18.

Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli L, Birman E, Viollet B, Ferbeyre G, Pollak MN (2012) Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) 5(4):536–543. doi:10.1158/1940-6207.capr-11-0536 CrossRef

19.

Lee SK, Lee JO, Kim JH, Kim SJ, You GY, Moon JW, Jung JH, Park SH, Uhm KO, Park JM, Suh PG, Kim HS (2011) Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells. J Cell Biochem 112(5):1259–1267. doi:10.1002/jcb.23000 CrossRefPubMed

20.

Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5):577–590CrossRefPubMed

21.

Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, DePinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754):1642–1646CrossRefPubMedPubMedCentral

22.

Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang Y, Lai X, Wei Y, Yu S, Zhang J, Liu W (2014) Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer 14:172. doi:10.1186/1471-2407-14-172 CrossRefPubMedPubMedCentral

23.

Hirsch HA, Iliopoulos D, Struhl K (2013) Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 110(3):972–977. doi:10.1073/pnas.1221055110 CrossRefPubMed

24.

Lonardo E, Cioffi M, Sancho P, Crusz S, Heeschen C (2015) Studying pancreatic cancer stem cell characteristics for developing new treatment strategies. J Vis Exp 100:e52801–e52801. doi:10.3791/52801 PubMed

25.

Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Kwon KI, Kim BH, Kim SK, Song GY, Jeong TC, Jeong HG (2011) Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162(5):1096–1108. doi:10.1111/j.1476-5381.2010.01101.x CrossRefPubMedPubMedCentral

26.

Ling S, Tian Y, Zhang H, Jia K, Feng T, Sun D, Gao Z, Xu F, Hou Z, Li Y, Wang L (2014) Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel7402/5fluorouracil cells. Mol Med Rep 10(6):2891–2897. doi:10.3892/mmr.2014.2614 PubMedPubMedCentral

27.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA (2010) Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 9(18):3831–3838CrossRef

28.

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890. doi:10.1016/j.cell.2009.11.007 CrossRefPubMed

29.

Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA (2010) Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 9(22):4461–4468CrossRefPubMed

30.

Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z (2014) Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem 386(1–2):63–71. doi:10.1007/s11010-013-1845-x CrossRefPubMed

31.

Zhao Z, Cheng X, Wang Y, Han R, Li L, Xiang T, He L, Long H, Zhu B, He Y (2014) Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. Plos One 9(4):e95884. doi:10.1371/journal.pone.0095884 CrossRefPubMedPubMedCentral

32.

Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao X, Huang S, Wang J, Li Z, Xie K (2015) Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget 6(14):12748–12762CrossRefPubMedPubMedCentral

33.

Jang SY, Kim A, Kim JK, Kim C, Cho YH, Kim JH, Kim CH, Lee JY (2014) Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. Anticancer Res 34(8):4127–4134PubMed

34.

Hsieh S-C, Tsai J-P, Yang S-F, Tang M-J, Hsieh Y-H (2014) Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Amino Acids 46(12):2809–2822CrossRefPubMed

35.

Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B (2014) Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun 452(3):746–752. doi:10.1016/j.bbrc.2014.08.154 CrossRefPubMed

36.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262 CrossRefPubMed

37.

Deng YH, Pu XX, Huang MJ, Xiao J, Zhou JM, Lin TY, Lin EH (2010) 5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells. Chin J Cancer 29(9):810–815CrossRefPubMed

38.

Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Saeki T, Tanaka I (2004) The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 488(1–3):213–218. doi:10.1016/j.ejphar.2004.02.019 CrossRefPubMed

39.

Sui X, Xu Y, Yang J, Fang Y, Lou H, Han W, Zhang M, Chen W, Wang K, Li D, Jin W, Lou F, Zheng Y, Hu H, Gong L, Zhou X, Pan Q, Pan H, Wang X, He C (2014) Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. Plos One 9(5):e97781. doi:10.1371/journal.pone.0097781 CrossRefPubMedPubMedCentral

40.

Li W, Wang Q-L, Liu X, Dong S-H, Li H-X, Li C-Y, Guo L-S, Gao J-M, Berger NA, Li L, Ma L, Wu Y-J (2015) Combined use of Vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res 8(2):139–148. doi:10.1158/1940-6207.capr-14-0128 CrossRef

41.

Lesan V, Ghaffari SH, Salaramoli J, Heidari M, Rostami M, Alimoghaddam K, Ghavamzadeh A (2014) Evaluation of antagonistic effects of metformin with Cisplatin in gastric cancer cells. Int J Hematol-Oncol Stem Cell Res 8(3):12–19PubMedPubMedCentral

42.

Cui XD, Lee MJ, Kim JH, Hao PP, Liu L, Yu GR, Kim DG (2013) Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. Hepatology 57(6):2248–2260. doi:10.1002/hep.26253 CrossRefPubMed

43.

Johnson PJ (2005) Non-surgical treatment of hepatocellular carcinoma. HPB 7(1):50–55. doi:10.1080/13651820410024076 CrossRefPubMedPubMedCentral

44.

Petrushev B, Tomuleasa C, Soritau O, Aldea M, Pop T, Susman S, Kacso G, Berindan I, Irimie A, Cristea V (2012) Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol 34(1):17–24PubMed

45.

Yang X, Sun D, Tian Y, Ling S, Wang L (2015) Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression. Tumour Biol 36(4):2957–2964. doi:10.1007/s13277-014-2926-5 CrossRefPubMed

46.

Bhardwaj V, Bhushan A, Lai JC, Tadinada SM (2012) Pancreatic cancer - molecular mechanism and targets. In: Sanjay K. Srivastava (ed) Failure of pancreatic cancer chemotherapy: consequences of drug resistance mechanisms. INTECH Open Access Publisher, Rijeka, pp 143–160

47.

Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, Huang H, DiPaola RS, Tan XL (2015) Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget 6(25):21208–21224CrossRefPubMedPubMedCentral

48.

Baron B, Wang Y, Maehara S-I, Maehara Y, Kuramitsu Y, Nakamura K (2015) Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. Anticancer Res 35(4):1941–1949PubMed

49.

Chai X, Chu H, Yang X, Meng Y, Shi P, Gou S (2015) Metformin increases sensitivity of pancreatic cancer cells to gemcitabine by reducing CD133 + cell populations and suppressing ERK/P70S6 K signaling. Sci Reports 5:14404. doi:10.1038/srep14404 CrossRef

50.

Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiora P, Sordi V, Lampasona V, Ceraulo D, Di Terlizzi G, Doglioni C, Falconi M, Piemonti L (2015) (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase 2 trial. Clin Cancer Res. doi:10.1158/1078-0432.ccr-15-1722 PubMed

51.

Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC (2007) Current management strategies for ovarian cancer. Mayo Clin Proc 82(6):751–770. doi:10.4065/82.6.751 CrossRefPubMed

52.

Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V (2011) Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (New York, NY) 13(5):483–491CrossRef

53.

Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. doi:10.1016/j.ajog.2014.10.026 PubMed

54.

Kim NY, Lee HY, Lee C (2015) Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. Int J Oncol 47(1):353–360. doi:10.3892/ijo.2015.3004 PubMed

55.

Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP (2011) Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126(3–5):113–120. doi:10.1016/j.jsbmb.2010.12.006 CrossRefPubMed

56.

Li X, Guo YR, Lin JF, Feng Y, Billig H, Shao R (2014) Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance. J Cancer 5(3):173–181. doi:10.7150/jca.8009 CrossRefPubMedPubMedCentral

57.

Uehara T, Mitsuhashi A, Tsuruoka N, Shozu M (2015) Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. Oncol Rep 33(2):744–750. doi:10.3892/or.2014.3611 PubMed

58.

Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, Pollak M, Lui L, Endt K, Schiess R, Ruschoff JH, Cathomas R, Gillessen S (2014) Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 66(3):468–474. doi:10.1016/j.eururo.2013.12.057 CrossRefPubMed

59.

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17(1):113–124. doi:10.1016/j.cmet.2012.12.001 CrossRefPubMed

60.

Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70(6):2465–2475. doi:10.1158/0008-5472.can-09-2782 CrossRefPubMed

61.

Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP, Oak CZ, MacLennan GT, Flask CA, Lindner DJ, Parker Y, Daneshgari F, Gupta S (2014) Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. Mol Cancer Ther 13(10):2288–2302. doi:10.1158/1535-7163.mct-14-0451 CrossRefPubMedPubMedCentral

62.

Babcook M, Sramkoski R, Fujioka H, Daneshgari F, Almasan A, Shukla S, Nanavaty R, Gupta S (2014) Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1-and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Cell Death Dis 5(11):e1536CrossRefPubMedPubMedCentral

63.

Saha A, Blando J, Tremmel L, DiGiovanni J (2015) Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice. Cancer Prev Res (Phila) 8(7):597–606. doi:10.1158/1940-6207.capr-15-0014 CrossRef

64.

Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302. doi:10.1200/jco.2009.19.6410 CrossRefPubMedPubMedCentral

65.

Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J (2012) Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32(5):1627–1637PubMed

66.

Soo JS-S, Ng C-H, Tan SH, Malik RA, Teh Y-C, Tan B-S, Ho G-F, See M-H, Taib NAM, Yip C-H, Chung FF-L, Hii L-W, Teo S-H, Leong C-O (2015) Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. Apoptosis Int J Program Cell Death 20(10):1373–1387. doi:10.1007/s10495-015-1158-5 CrossRef

67.

Zakikhani M, Blouin MJ, Piura E, Pollak MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123(1):271–279. doi:10.1007/s10549-010-0763-9 CrossRefPubMed

68.

Wang Y, Wei J, Li L, Fan C, Sun Y (2015) Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells. Oncol Res 22(4):193–201. doi:10.3727/096504015x14348950540999 CrossRef

69.

Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA (2011) The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 126(2):355–364. doi:10.1007/s10549-010-0924-x CrossRefPubMed

70.

Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B, Menendez JA (2012) Metformin-induced preferential killing of breast cancer initiating CD44 + CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2 + human breast cancer xenografts. Oncotarget 3(4):395–398CrossRefPubMedPubMedCentral

71.

Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD (2011) Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 10(17):2959–2966CrossRefPubMed

72.

Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA (2010) Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9(1):188–197CrossRefPubMed

73.

Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X (2014) Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) 7(2):199–210. doi:10.1158/1940-6207.capr-13-0181 CrossRef

74.

Lau YK, Du X, Rayannavar V, Hopkins B, Shaw J, Bessler E, Thomas T, Pires MM, Keniry M, Parsons RE, Cremers S, Szabolcs M, Maurer MA (2014) Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget 5(21):10503–10517CrossRefPubMedPubMedCentral

75.

Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17(12):3993–4005. doi:10.1158/1078-0432.ccr-10-2243 CrossRefPubMed

76.

Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181. doi:10.1038/nrc2088 CrossRefPubMed

77.

Soria JC, Mok TS, Cappuzzo F, Janne PA (2012) EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 38(5):416–430. doi:10.1016/j.ctrv.2011.10.003 CrossRefPubMed

78.

Chen H, Yao W, Chu Q, Han R, Wang Y, Sun J, Wang D, Wang Y, Cao M, He Y (2015) Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Letters 369(1):97–102. doi:10.1016/j.canlet.2015.08.024 CrossRefPubMed

79.

Kitazono S, Takiguchi Y, Ashinuma H, Saito-Kitazono M, Kitamura A, Chiba T, Sakaida E, Sekine I, Tada Y, Kurosu K, Sakao S, Tanabe N, Iwama A, Yokosuka O, Tatsumi K (2013) Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol 43(6):1846–1854. doi:10.3892/ijo.2013.2120 PubMedPubMedCentral

80.

Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, Li K, Chen H, Sun F, Yang Z, Jiang J, He Y (2014) Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 20(10):2714–2726. doi:10.1158/1078-0432.ccr-13-2613 CrossRefPubMed

81.

Chiu HC, Chou DL, Huang CT, Lin WH, Lien TW, Yen KJ, Hsu JT (2011) Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochem Pharmacol 81(11):1263–1270. doi:10.1016/j.bcp.2011.03.003 CrossRefPubMed

82.

Ko JC, Chiu HC, Wo TY, Huang YJ, Tseng SC, Huang YC, Chen HJ, Syu JJ, Chen CY, Jian YT, Jian YJ, Lin YW (2013) Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells. Lung Cancer (Amsterdam, Netherlands) 82(3):397–406. doi:10.1016/j.lungcan.2013.09.011 CrossRef

83.

Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D’Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F (2013) Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res 19(13):3508–3519. doi:10.1158/1078-0432.ccr-12-2777 CrossRefPubMed

84.

Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC (2013) Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am J Respir Cell Mol Biol 49(2):241–250. doi:10.1165/rcmb.2012-0244OC CrossRefPubMed

85.

Chen YQ, Chen G (2015) Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice. J Cancer Res Ther 11(2):324–330. doi:10.4103/0973-1482.151444 CrossRefPubMed

86.

Teixeira SF, Guimaraes IdS, Madeira KP, Daltoe RD, Silva IV, Rangel LBA (2013) Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells. J Bras Pneumol 39(6):644–649CrossRefPubMedPubMedCentral

87.

Tseng SC, Huang YC, Chen HJ, Chiu HC, Huang YJ, Wo TY, Weng SH, Lin YW (2013) Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel. Biochem Pharmacol 85(4):583–594. doi:10.1016/j.bcp.2012.12.001 CrossRefPubMed

88.

Xiao Z, Sperl B, Ullrich A, Knyazev P (2014) Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. Oncotarget 5(24):12877CrossRefPubMedPubMedCentral

89.

Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF, Bernards R (2015) Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer 136(6):1434–1444. doi:10.1002/ijc.29113 CrossRefPubMed

90.

Lin Y-C, Wu M-H, Wei T-T, Lin Y-C, Huang W-C, Huang L-Y, Lin Y-T, Chen C-C (2014) Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget 5(1):298–308PubMedPubMedCentral

91.

Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S (2015) Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget 6(2):969CrossRefPubMed

92.

Cerezo M, Tomic T, Ballotti R, Rocchi S (2015) Is it time to test biguanide metformin in the treatment of melanoma? Pigment Cell Melanoma Res 28(1):8–20CrossRefPubMed

93.

Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A (2011) Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med 9:76. doi:10.1186/1479-5876-9-76 CrossRefPubMedPubMedCentral

94.

Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S (2014) Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol 45(2):567–574. doi:10.3892/ijo.2014.2450 PubMedPubMedCentral

95.

Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L (2011) Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 651(1–3):41–50. doi:10.1016/j.ejphar.2010.11.005 CrossRefPubMed

96.

Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA (2013) Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 24(9):469–480. doi:10.1016/j.tem.2013.05.004 CrossRefPubMed

97.

Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2010) Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle (Georgetown, Tex) 9(6):1057–1064CrossRef

98.

Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81–98CrossRefPubMed

99.

Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell’Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B (2013) The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 109(11):2792–2797. doi:10.1038/bjc.2013.657 CrossRefPubMedPubMedCentral

100.

Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, Taback B, Ahmad A, Cremers S, Hibshoosh H, Maurer M, Hershman DL (2014) Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 32(4):150–157. doi:10.3109/07357907.2014.889706 CrossRefPubMedPubMedCentral

101.

Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2(9):778–790. doi:10.1158/2159-8290.cd-12-0263 CrossRefPubMed

Title: Combinational strategies of metformin and chemotherapy in cancers
Authors: Hui-Hui Zhang
Xiu-Li Guo
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3037-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Reply to Prof Ian J. Cohen

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency

Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective

Keynote webinar | Spotlight on antibody–drug conjugates in cancer